Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06385236
PHASE4

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

Sponsor: University of California, San Diego

View on ClinicalTrials.gov

Summary

In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions, and may ultimately lead to a change in the way that asthma patients are evaluated for potential personalized therapies and maximize the probability that the subject will respond to treatment.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-02-19

Completion Date

2028-01-31

Last Updated

2024-08-19

Healthy Volunteers

No

Interventions

BIOLOGICAL

Dupilumab

Dupilumab, an interleukin-4 receptor treatment, will be administered through a subcutaneous injection, the initial dose of 600 mg will be administered at two different injection sites (300 mg per injection), followed by a single dose of 300 mg administered every other week (Q2W). Participants may self-administer injection after proper training.

BIOLOGICAL

Benralizumab

Benralizumab, an interleukin-5 receptor treatment, will be administered through a subcutaneous injection every 4 weeks (Q4W). Participants may self-administer injection after proper training.

Locations (3)

Mayo Clinic

Scottsdale, Arizona, United States

University of California, San Diego

La Jolla, California, United States

Yale University

New Haven, Connecticut, United States